July 8, 2013:
Reuters: RegeneCure Launches Implant for Pet Surgery, Eyes Human Market
June 4, 2013:
RegeneCure Starts Worldwide Veterinary Distribution of BoneCure Membrane Implant for Acceleration of Fracture Healing and Carpal Arthrodesis
Jerusalem, Israel, June 4, 2013 / B3C newswire / - RegeneCure Ltd., a developer of novel regenerative membrane implant technology for the treatment of human and animal bone fractures, announced today that the company has started to distribute its BoneCure® Membrane product to the veterinary market in Europa, the United States and Canada, Asia and Australia.
The use of the BoneCure Membrane for carpal arthrodesis is a major breakthrough in the surgery of companion animals that offers many advantages over the traditional “Gold Standard” procedure of harvesting an autogenous bone graft. This procedure, described at the BoneCure website, prevents patient morbidity and pain, reduces the risks of infection and fracture at the donor site, saves operating time and eliminates the need for a second incision.
March 12, 2013:
RegeneCure's Membrane Implant Shows 40% Accelerated Healing Time of Severe Bone Fractures in Pet Clinical Study
Jerusalem, Israel, March 12, 2013 / B3C newswire / RegeneCure announced today the successful results of a clinical study in pets using the company's regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies. The product was also demonstrated to be safe in all of the study participants.
"The healing time for animals treated in the participating clinical study sites with injuries that normally take from five to twelve months was in many cases reduced to just eight weeks," said Dr. Michal Limor, VP Medical Affairs of RegeneCure.
The multi-center trial was conducted at leading veterinary clinics in England, Germany and Israel. The study included 35 mature dogs and cats with different bone fractures including delayed healing and non-union conditions.
In Vitro Study of a Novel Polymeric Mesenchymal Stem-Cell Coated Membrane
Ada Grin, Yoel Sasson, Shaul Beyth, Rami Mosheiff, Jacob Rachmilewitz, Michael Friedman
Journal of Drug Delivery Science Technology 19 (4) (2009): 241-246.
Abstract: The objective of the study was to develop and study in vitro polymeric membrane that enables adhesion, proliferation, and differentiation of mesenchymal stem cells on its surface. We screened several membrane formulations with varying plasticizer types and concentrations for their ability to support MSC adherence and growth. To that end, MSCs were isolated from human bone marrow, and cell adherence to membrane, cell membrane interaction and cell morphology were observed using scanning electron microscopy (SEM) and fluorescent microscopy. MSCs adhered well to ammonio methacrylate copolymer type A (AMCA) membranes prepared with the various plasticizers and revealed spindle monolayer shape with podia, similar to polystyrene dishes. MSCs proliferated and differentiated only on AMCA membrane with polyethyleneglycol 400 (PEG400) as plasticizer. Furthermore, the membrane surfaces were characterized using SEM and their porosity was measured. These data confirm that MSCs maintain their stem cell traits after adhesion to membrane.